BamSEC and AlphaSense Join Forces
Learn More

SCYNEXIS Inc. – Material Contracts

NASDAQ: SCYX    
Share price (11/6/26): $3.50    
Market cap (11/6/26): $34.8 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 70 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Contract Clauses and Sections
12/34/56
EX-10.1
from 10-Q 18 pages Employment Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Amendment to Employment Agreement
12/34/56
EX-10.1
from 10-Q 2 pages Amendment to Employment Agreement
12/34/56
EX-10.1
from 10-Q 69 pages Asset Purchase Agreement Between Scynexis, Inc., as Buyer and Poxel SA as Seller Dated as of March 30, 2026
12/34/56
EX-10.2
from 8-K 25 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 44 pages Securities Purchase Agreement
12/34/56
EX-10.31
from 10-K 6 pages Binding Memorandum of Understanding for Amendment to Exclusive License Agreement
12/34/56
EX-10.17
from 10-K 3 pages SCYNEXIS Non-Employee Director Compensation Policy
12/34/56
EX-10.2
from 10-Q 3 pages Scynexis Non-Employee Director Compensation Policy Revised April 2024
12/34/56
EX-10.1
from 10-Q 18 pages Employment Agreement
12/34/56
EX-10.41
from 10-K 13 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.21
from 10-K 3 pages Scynexis Non-Employee Director Compensation Policy Revised December 2023; Effective January 1, 2024
12/34/56
EX-10.3
from 10-Q 3 pages Third Amendment to Termination and License Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Second Amendment to Termination and License Agreement
12/34/56
EX-10.1
from 10-Q 2 pages December 3, 2014 By:___/S/ Iain Dukes 12/11/14 Name:___iain Dukes Title:___svp, Research Science
12/34/56
EX-10.1
from 10-Q 8 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Redacted Pursuant to Item 601(a)(6) of Regulation S-K
12/34/56
EX-10
from 10-Q 9 pages October 20, 2022 Christine Rose Coyne
12/34/56
EX-10
from 10-Q 129 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Exclusive License Agreement by and Between Scynexis, Inc. and Glaxosmithkline Intellectual Property (No. 3) Limited Dated as of March 30, 2023
12/34/56
EX-10
from 10-K 17 pages Employment Agreement
12/34/56